‘Significant step forward’: Diabetes health and research leaders welcome government response to landmark inquiry

The Australian Diabetes Society (ADS and its divisions NADC and DFA), Australian Diabetes Educators Association (ADEA), Australasian Diabetes in Pregnancy Society (ADIPS), and the Australian and New Zealand Society for Paediatric Endocrinology and Diabetes (ANZSPED) have welcomed the Australian Government’s response to the Parliamentary Inquiry into Diabetes. The government has supported nine of the 23 recommendations in principle, including initiatives to improve equitable access to diabetes care, strengthen the diabetes health workforce, enhance public awareness, expand access to medicines and improve data and research coordination.

Download the joint media release by the ADS, ADEA, ADIPS and ANZSPED (Posted: 14 May 2026) – PDF

The post May 2026: Government Response to the Parliamentary Inquiry into Diabetes appeared first on Australian Diabetes Society.

Official Launch of the National Diabetes Research Strategy for 2026-2035

In recognition of World Diabetes Day 2025, the Australian Diabetes Society is proud to announce the official launch of the National Diabetes Research Strategy (2026-2035). This comprehensive strategy provides a roadmap to strengthen world-class diabetes research in Australia, with the aim of improving health outcomes and enhancing the quality of life for Australians living with diabetes.

This strategy has been developed by the Australian Diabetes Society, Australian Diabetes Educators Association, Breakthrough T1D, Australian Diabetes in Pregnancy Society, Diabetes Australia, Diabetes Victoria, Australia and New Zealand Society of Paediatric Endocrinology and Diabetes, Endocrine Society of Australia and Australia and New Zealand Obesity Society.

Download the National Diabetes Research Strategy (2026-2035) (Posted: November 2025) – PDF

The post November 2025: Launch of the National Diabetes Research Strategy 2026-2035 appeared first on Australian Diabetes Society.

Updated ADS Living Clinical Guideline on MAFLD in People with Diabetes

The Australian Diabetes Society (ADS) has made important updates to the ADS MAFLD living clinical guideline with respect to the Fib-4 calculation and the approval of medications by the FDA.

Download the updated ADS Clinical Care Consensus Living Guideline for Specialist Assessment, Referral and Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease in People with Diabetes (September 2025) – PDF

Updated Australian Obesity Management Algorithm

The Australian Diabetes Society has updated the Australian Obesity Management Algorithm position statement to indicate that tirzepatide (Mounjaro) is TGA approved for the treatment of obesity.

Download the updated Australian Obesity Management Algorithm Position Statement (September 2025) – PDF

The post September 2025: Updated ADS MAFLD Living Clinical Guideline & Updated Australian Obesity Management Algorithm appeared first on Australian Diabetes Society.

National Diabetes Research Strategy for 2026-2035

A comprehensive strategy to drive impactful, equitable and sustainable diabetes research and improved diabetes care for the benefit of all Australians.

The National Diabetes Research Strategy (2026–2035) presents a unified national vision to transform Australia’s response to diabetes through a comprehensive forward-looking research and innovation agenda. It is grounded in the urgent need to reduce the growing burden of diabetes on individuals, families, communities, healthcare systems and the national economy. With an alarming decline in diabetes research funding and our next generation research workforce at a critical tipping point, immediate action is vital, otherwise Australia risks forfeiting its global leadership in diabetes health innovation. Guided by the priorities of the Australian National Diabetes Strategy (2021-2030) and informed by the 2024 Parliamentary Inquiry into Diabetes, this strategy sets bold, long-term goals to address the complexity of diabetes in Australia.

This strategy has been developed by the Australian Diabetes Society, Australian Diabetes Educators Association, Breakthrough T1D, Australia and New Zealand Society of Paediatric Endocrinology and Diabetes, Diabetes Australia, Diabetes Victoria, Endocrine Society of Australia, Australia and New Zealand Obesity Society, Research Australia and Diabetes Feet Australia.

Download the National Diabetes Research Strategy (2026-2035) (Posted: August 2025) – PDF

Please note that the document is currently in draft form. If you would like to provide feedback on the strategy, please send an email to the ADS CEO, A/Prof Sof Andrikopoulos, at: ceo@diabetessociety.com.au

Updated Australian Obesity Management Algorithm

The Australian Diabetes Society has updated the Australian Obesity Management Algorithm position statement, specifically the Pharmacotherapy Table 1.

Download the updated Australian Obesity Management Algorithm Position Statement (August 2025) – PDF

The post August 2025: National Diabetes Research Strategy (2026-2035) & Updated Australian Obesity Management Algorithm appeared first on Australian Diabetes Society.

New diabetes-related foot disease (DFD) national strategy

The Australian Diabetes Society and Diabetes Feet Australia are committed to improving the foot health outcomes for people living with diabetes and in turn help reduce the large health burdens caused by diabetes-related foot disease on the nation, and we’re excited to launch the new Australian strategy for foot health and disease in diabetes 2030!

This strategy is a new plan to help people with diabetes take better care of their feet and prevent serious foot problems and targets how to improve the foot health of all people with diabetes in three main ways.

And to officially launch the Australian strategy for foot health and disease in diabetes 2030, we’ve developed an insightful webinar where we chat with some of the authors about why we need a new DFD strategy and discuss how and why the nine key national priority goals can help improve the foot health of people living with diabetes. So, head to the Diabetes Feet Australia website to learn all about the new national strategy and how we can work collaboratively to reduce the burden of diabetes-related foot disease, improve patient outcomes, and advocate for equitable access to care across Australia.

Download the Australian Strategy for Foot Health and Disease in Diabetes 2030 – PDF

The post July 2025: Australian Strategy for Foot Health and Disease in Diabetes 2030 appeared first on Australian Diabetes Society.

Based on new evidence from clinical studies and to make recommendations clearer, clinical practice recommendations for patients taking GLP-1 RA and dual GLP-1/GIP RAs prior to anaesthesia or sedation have been updated.

Representatives from the Australian Diabetes Society, Australian and New Zealand College of Anaesthetists, Gastroenterological Society of Australia, National Association of Clinical Obesity Services, and Australian & New Zealand Metabolic and Obesity Surgery Society have developed the revised recommendations, which now include a decision-aid flowchart linked to explanatory statements.

They now also include a clear statement regarding the recommendation not to withhold these drugs prior to a procedure.

The revised document is available here. Please send any feedback or queries to admin@diabetessociety.com.au

The post Updated clinical practice recommendations regarding the periprocedural use of GLP-1RAs and GLP-1/GIPRAs (April 2025) appeared first on Australian Diabetes Society.

Joint ADS/ANZSNM guideline for FDG PET/CT imaging in patients with type 1 and type 2 diabetes (August 2024)

A joint guideline by the Australian Diabetes Society (ADS) and Australian and New Zealand Society of Nuclear Medicine (ANZSNM) for PET/CT imaging in patients with type 1 and type 2 diabetes.

The purpose of the guideline is to assist medical, nursing and nuclear medicine staff to prepare and manage people living with diabetes undergoing a PET scan. This guideline is for the provision of advice only and does not replace clinical decision making in individual patients or specific protocols adapted for individual centres.

Download the Joint ADS/ANZSNM guideline for FDG PET/CT imaging in patients with type 1 and type 2 diabetes (August 2024)

Consensus Statement: The Use of Diabetes Specific Nutritional Formulas in Type 2 Diabetes (August 2024)

Developed by an expert working group of representatives from the Australian Diabetes Society (ADS), Australian Diabetes Educators Association (ADEA), Royal Australian College of General Practitioners (RACGP) and Dietitians Australia, this consensus statement aims to provide healthcare professionals with a comprehensive understanding of Diabetes Specific Nutritional Formulas (DSNFs) and their potential role in managing T2D, and to offer guidance for their application in clinical practice, based on a review of the current evidence as well as expert opinions.

This consensus statement has been written for healthcare professionals who manage people with type 2 diabetes (T2D), including general practitioners (GPs) and other primary healthcare team members.

Download the Consensus Statement: The Use of Diabetes Specific Nutritional Formulas in Type 2 Diabetes (August 2024)

The post August 2024: New ADS Guideline and Consensus Statement appeared first on Australian Diabetes Society.

Revised Australian Obesity Management Algorithm

The Australian Diabetes Society (ADS) has updated the Australian Obesity Management Algorithm position statement.

Download the updated Australian Obesity Management Algorithm Position Statement (July 2024) – PDF

Treatment Management Plans: Type 2 Diabetes & Obesity

The ADS has a dedicated website specifically on Treatment Management Plans: Type 2 Diabetes & Obesity. The website features type 2 diabetes case studies and an interactive obesity treatment algorithm designed to assist clinicians in treatment options for Australian adults living with obesity and its co-morbidities.

Website URL: https://treatment.diabetessociety.com.au

The post Updated Australian Obesity Management Algorithm appeared first on Australian Diabetes Society.

A consensus clinical practice recommendation endorsed by the Australian Diabetes Society (ADS), National Association of Clinical Obesity Services (NACOS), Gastroenterological Society of Australia (GESA) and Australian and New Zealand College of Anaesthetists (ANZCA).

In response to recent case reports of retained gastric contents and pulmonary aspiration during sedation for endoscopic procedures or general anaesthesia in people with diabetes and/or obesity treated with GLP-1 receptors agonists (GLP-1RAs), a clinical practice recommendation regarding the periprocedural use of GLP-1RAs/GIP Receptor Agonists (GIPRAs) has been co-authored by representatives from the Australian Diabetes Society (ADS), National Association of Clinical Obesity Services (NACOS), Gastroenterological Society of Australia (GESA) and Australian and New Zealand College of Anaesthetists (ANZCA). The below represents a consensus based on review of currently available evidence and consensus expert opinion. Although the current level of evidence is weak to inform a guideline, this document was written to mitigate the risk of pulmonary aspiration with the periprocedural use of GLP-1RAs/GIPRAs which, although rare, is potentially fatal.

Download the Clinical Practice Recommendation On Periprocedural Use Of GLP-1/GIP Receptor Agonists (June 2024)

The post Clinical Practice Recommendation On Periprocedural Use Of GLP-1/GIP Receptor Agonists (June 2024) appeared first on Australian Diabetes Society.

Revised Australian Type 2 Diabetes Glycaemic Management Algorithm

The Australian Diabetes Society (ADS) has updated the Australian Type 2 Diabetes Glycaemic Management Algorithm diagram to reflect the recent Pharmaceutical Benefits Scheme (PBS) restriction changes to type 2 diabetes medicines.

Download the updated Australian Type 2 Diabetes Glycaemic Management Algorithm (June 2024) – PDF

Treatment Management Plans: Type 2 Diabetes & Obesity

The ADS has a dedicated website specifically on Treatment Management Plans: Type 2 Diabetes & Obesity. The website features type 2 diabetes case studies and an interactive obesity treatment algorithm designed to assist clinicians in treatment options for Australian adults living with obesity and its co-morbidities.

Website URL: https://treatment.diabetessociety.com.au

The post Updated T2D Management Algorithm appeared first on Australian Diabetes Society.